DiscoverThe IMID ForumDiscussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA
Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Update: 2025-09-18
Share

Description

Join Dr Sofia Ramiro and Professor Xenofon Baraliakos as they discuss the top publications in the world of axSpA. This month, the conversation covered the effectiveness of ixekizumab in real-world patients with axSpA and PsA, and the real‑world comparison of clinical effectiveness of UPA, TNF inhibitors or IL‑17 inhibitors in patients with axSpA after switching from an initial TNF inhibitor.
Comments 
In Channel
Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

2025-10-0918:31

Author Interview: Doctor David Kellner, September 2025

Author Interview: Doctor David Kellner, September 2025

2025-10-0222:44

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

2025-09-2508:44

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

2025-09-1820:52

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

2025-09-0407:41

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

2025-08-2828:57

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

2025-08-1445:23

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

2025-08-0717:45

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

2025-07-3113:24

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

2025-07-1016:44

Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash

Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash

2025-07-0341:27

EULAR 2025 Review Podcast

EULAR 2025 Review Podcast

2025-07-0201:05:19

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

2025-06-2615:20

EULAR 2025 Highlights: Day 4

EULAR 2025 Highlights: Day 4

2025-06-1403:25

EULAR 2025 Highlights: Day 3

EULAR 2025 Highlights: Day 3

2025-06-1302:36

Discussing PsA: Real-world data on biologic switching and the development of EMMs

Discussing PsA: Real-world data on biologic switching and the development of EMMs

2025-06-1223:11

EULAR 2025 Highlights: Day 2

EULAR 2025 Highlights: Day 2

2025-06-1204:39

EULAR 2025 Highlights: Day 1

EULAR 2025 Highlights: Day 1

2025-06-1104:03

EULAR 2025 Preview Podcast

EULAR 2025 Preview Podcast

2025-06-0925:23

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA

2025-06-0510:25

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

The Immune-Mediated Inflammatory Disease Forum